The International Cancer Alliance for Research
and Education (ICARE) is a non-profit organization,
501(c) (3), that supports, initiates and directs cutting edge cancer research projects
and provides high-quality, focused, user-friendly
cancer information to each patient as well as their
physician on an ongoing, personalized basis.
ICARE is devoted to creating investigative partnerships among patients,
physicians, and cancer researchers. Toward this end, the
mission of ICARE is threefold:
- To increase the flow of new, life-saving therapy
information to cancer patients and their doctors. To
convene investigative teams (I-Teams), composed of the
world's top doctors, scientists, students and
patients/advocates, that will attempt to define all
available therapy options for the specific cancers
represented in that team.
- To hasten the movement of new therapy research
from the laboratory to the patient through support of
clinical trials and research.
- To serve as an active advocate for creativity and
innovative thinking in cancer research.
KEY is to Triangulate the best minds in science, medicine and society
to think/act to create the best chance of survival for
individual Cancer Patients
ICare is here to help YOU build YOUR
triangle so you can make the most well-informed
therapeutic decisions possible on your "road to recovery".
NEW Approach to Cancer Patient Care and to Therapy Development Through the I-TEAM Process
the traditional cancer treatment scenario, the physician is the
principal and often the sole provider of information on therapy
options. However, it is difficult even for the most diligent physician
to keep up with treatment advances, promising clinical trials and new
therapy options. ICARE seeks to work with you and your doctor to insure
that all available and approved therapeutic options are considered in
designing your treatment plan. In addition, there are currently
few mechanisms for community doctors and their cancer patients to
provide feedback, support and inspiration to the very people who are
responsible for new drug discovery --- the academic and industry
scientist around the globe.
Therefore, the International Cancer Alliance for Research and Education
(ICARE), a non-profit organization, 501(c) (3), was initiated in 1985 in Bethesda,
MD by several prominent cancer
scientists from around the world. ICARE was originally organized as a
vehicle for cancer “think tanks” that focused on identifying obstacles to
creativity and innovation in cancer research laboratories. Over the years, ICARE created numerous
information and research programs designed to increase patient survival by
increasing the flow of therapy information to doctors and patients alike. In general, ICARE’s symposia, its clinical
trial matching programs, and its publications (Cancer Therapy Reviews,
Pharmaceutical Updates, Etc.) targeted broad audiences of cancer patient and
In recent years however, ICARE’s programs began to
shift in focus from just providing therapy information to patients to
identifying, initiating, and funding cutting-edge research projects targeting
the tumors of individual patients. These
innovative projects emphasized research strategies that could directly lead
to discovery and faster development of therapies that had much higher
efficacy and less toxicity. This shift
was accelerated in 2010 when some of the ICARE global scientists accepted the
challenge of partnering with individual cancer patients and their doctors to
form a type of “Manhattan Project” that would try and find viable solutions
in “real time” for immediate clinical issues facing the doctor and patient.
In particular from 2010 to 2012,
ICARE was recruited and funded to establish personalized medical research
projects on behalf 3 individuals with advanced cancers --- the first with a
rare form of liver cancer and the second and third with two different types of
metastatic melanoma. During that period,
a ten-step innovative research process (the I-Team Process) evolved that led to
the discovery and evaluation of more than thirty new drugs or approaches to be
considered by the doctors of these three individuals.
It should be noted that, in less
than two years, with limited, but unrestricted funding, ICARE recruited a
team of more than 40 world class scientists to focus their expertise and lab
work on the urgent therapy needs of individual cancer patients. As a
result, over 30 new therapeutic approaches have been discovered and many
of these are currently in the clinical pipeline. Many of the new options
are applicable to other types of cancer. In addition, new targets and ideas for new therapies
continue to emanate from I-Team collaborative projects.
Thus, ICARE is currently addressing its mission objectives
by creating “individual” investigative partnerships which begin with one
patient, one doctor and one cancer researcher. As global participants are added, these
Investigative Teams (I-Teams) allow individual patients and their doctors to
participate in real-time, personalized academic research projects that are driven
by patient needs and are not limited by institutional and national boundaries.
These I-Team medical research projects, conducted under the full guidance of
FDA human research policies, currently constitute the majority of ICARE efforts
to achieve its three-part mission. The discovery objectives of the I-Team process are:
The objectives of each I-Team are to:
1) Identify ALL potential therapeutic options
around the globe that might helf the doctor treat this particular patient. To
the extent that time and money will allow, every option should at least be
considered even if it has not been used for the I-Team cancer type.
options can be drawn from four categories:
a. Standard medicine (i.e. FDA approved)
b. Clinical Trial
c. Cutting-Edge, pre-clinical research
options that are currently in development
d. Creation of new agents or technology
options through insight gained from the personalized I-Team research
2) Evaluate any supportive data and where
possible, test each option in credible, informative, pre-clinical biological
3) Personalize, through biological and genetic
testing on fixed, frozen or living tumor specimens. Try to predict and
prioritize which options are most likely to work for this particular patient.
4) Accelerate rapid clinical development of, and
access to agents which hold promise for the I-Team patient.
invites you to join and/or support the I-TEAM PROCESS and our campaign
to test our hypothesis that "Creativity, and perhaps only creativity,
will lead to treatment solutions for someone you love".